Delivery Order SPE2DE24DA017-SPE2D625F1QLV
- Not listed
- Arthrex Inc., a Naples, Florida-based leader in minimally invasive orthopedic medical technologies, was awarded a delivery order valued at $3,029.40 on August 27, 2025, for the ACP MAX PRP System with ACDA (autologous conditioned plasma). This fixed-price delivery order with economic price adjustment is scheduled for completion by September 2, 2025, and represents performance under Arthrex's larger indefinite delivery contract with the Defense Logistics Agency's Medical Supply Chain. The order...
- Arthrex Inc., a Naples, Florida-based orthopedic medical device manufacturer, was awarded a delivery order valued at $17,661.60 on May 30, 2025, for an ACP MAX PRP (Autologous Conditioned Plasma Maximum Platelet-Rich Plasma) System for overseas and European use. This fixed-price contract with economic price adjustment represents a task order issued under Arthrex's larger Indefinite Delivery Contract (SPE2DE24D0020) with the Defense Logistics Agency's Medical Supply Chain, a $471 million...
- Arthrex Inc., a leading global provider of minimally invasive orthopedic medical technologies based in Naples, Florida, has been awarded a delivery order valued at $1,817.64 for an ACP MAX PRP System with ACDA under a Defense Logistics Agency Medical Supply Chain contract. The award, announced on August 29, 2025, is a fixed-price delivery order with economic price adjustment provisions and is set to be completed by September 4, 2025. This delivery order falls under Arthrex's larger Indefinite...
- Arthrex Inc., a Naples, Florida-based orthopedic medical device manufacturer, received a $52,879.14 fixed-price delivery order from the Defense Logistics Agency's Medical Supply Chain on August 4, 2025, for an ACP MAX PRP System with ACDA technology. This delivery order represents a task order under Arthrex's larger Indefinite Delivery Contract (SPE2DE24D0020) valued at $471 million and running through September 1, 2029. The contract carries no set-aside designation, reflecting Arthrex's...
- Arthrex Inc., a global leader in minimally invasive orthopedic medical technologies headquartered in Naples, Florida, was awarded a delivery order valued at $7,270.56 on September 12, 2025, for the ACP MAX PRP System with ACDA. This fixed-price delivery order with economic price adjustment falls under the Defense Logistics Agency's Medical Supply Chain, a defense-focused federal agency responsible for supplying medical products to Department of Defense and Department of Veterans Affairs...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a $1,817.64 fixed-price delivery order to Arthrex Inc. on June 2, 2025, with a completion date of June 5, 2025. This order falls under Arthrex's existing indefinite delivery contract (IDC SPE2DE24D0020) valued at $471.0 million and running through September 1, 2029. The delivery order is for ACP MAX PRP System components with ACDA integration, which Arthrex will supply to the Naples, Florida location. The award was not set aside...
- The U.S. Department of Defense's Medical Supply Chain awarded a delivery order valued at $10,731.60 to Arthrex Inc. on September 9, 2025, for the supply of ARTHREX ANGEL PRP Kits (US Tray). This fixed-price contract with economic price adjustment is set to be completed by September 12, 2025, and will be performed at Arthrex's Naples, Florida facility. The award represents a task order issued under Arthrex's larger Indefinite Delivery Contract (SPE2DE24D0020) with the Defense Logistics Agency,...
- Arthrex Inc., a Naples, Florida-based leader in minimally invasive orthopedic medical technologies, received a delivery order from the Defense Logistics Agency's Medical Supply Chain on September 4, 2025, for the Arthrex ACP Double Syringe System. This fixed-price delivery order, valued at $3,300, is scheduled for completion by September 9, 2025, and represents a task order issued under Arthrex's larger Indefinite Delivery Contract (SPE2DE24D0020) with the Defense Logistics Agency, valued at...
- This is a delivery order awarded by the Defense Logistics Agency's Medical Supply Chain to Arthrex Inc., a global leader in minimally invasive orthopedic medical technologies. The $4,593.65 fixed-price contract with economic price adjustment is for the ACP MAX PRP SYSTEM (OUS/EU), a specialized medical device used for the extraction and concentration of platelet-rich plasma. Arthrex holds a larger $471,048,172.66 Indefinite Delivery Contract (IDC) with the Defense Logistics Agency, identified as...
- Arthrex Inc., a Naples, Florida-based leader in minimally invasive orthopedic medical technologies, was awarded a $2,475 fixed-price delivery order on August 8, 2025, for the Arthrex ACP Double Syringe System. The contract, issued by the Defense Logistics Agency's Medical Supply Chain, carries an ultimate completion date of August 13, 2025, and represents a non-set-aside award. This delivery order falls under the company's larger Indefinite Delivery Contract (SPE2DE24D0020) with the Defense...
- SPE2DE24DA017Indefinite Delivery Contract
- SPE2DE24DA017-SPE2D625F1QLVDelivery Order
The U.S. Department of Defense's Medical Supply Chain awarded a $3,960 delivery order to Arthrex Inc. on August 21, 2025, for the ACP MAX PRP System (OUS/EU). This fixed-price contract with economic price adjustment represents task order activity under Arthrex's larger Indefinite Delivery Contract (SPE2DE24D0020) with the Defense Logistics Agency, valued at $471 million and spanning June 2024 through September 2029. The delivery order is not designated as a set-aside and is scheduled for completion by August 26, 2025, with performance at Arthrex's Naples, Florida facility. Arthrex Inc., a global leader in minimally invasive orthopedic medical technologies headquartered in Naples, Florida, continues to support the Department of Defense and Veterans Affairs through its comprehensive orthopedic product offerings. The ACP MAX PRP System represents the company's platelet-rich plasma technology, which augments Arthrex's broader portfolio of surgical implants, arthroscopic instruments, and specialized surgical kits delivered to government healthcare systems. As a for-profit corporation with a strong competitive position in the federal marketplace, Arthrex has demonstrated substantial capability in meeting DoD and VA requirements, having received over $550,000 in delivery orders under its primary IDC to date.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.0k | 8/21/25 |